• Orchestra BioMed outlined two pivotal-stage cardiovascular programs, led by AVIM Therapy delivered via dual-chamber pacemakers for uncontrolled hypertension and hypertensive heart disease.
• BACKBEAT Global pivotal trial targets enrollment completion by end of Q3 2026, late-breaking primary endpoint data presentation in Q2 2027, followed by FDA marketing application if endpoints are met.
• Medtronic holds exclusive global commercial rights for pacemaker-indicated hypertension patients, with revenue share of $500 to $1,600 per AVIM-enabled device; collaboration includes a $61.6 million equity investment and $20 million in strategic capital.
• Virtue SAB sirolimus AngioInfusion balloon program targets coronary and peripheral artery disease; Virtue U.S. pivotal trial enrollment continues with completion targeted in 2027.
• Company pegged annual global market opportunity at more than $17 billion for AVIM Therapy, more than $10 billion for Virtue SAB.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orchestra Biomed Holdings Inc. published the original content used to generate this news brief on May 14, 2026, and is solely responsible for the information contained therein.